Trade Pliant Therapeutics, Inc. - PLRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02354% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001318% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.46 |
| Open | 1.47 |
| 1-Year Change | -89.85% |
| Day's Range | 1.42 - 1.51 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2025 | 1.42 | -0.05 | -3.40% | 1.47 | 1.51 | 1.42 |
| Mar 27, 2025 | 1.46 | 0.05 | 3.55% | 1.41 | 1.48 | 1.40 |
| Mar 26, 2025 | 1.43 | -0.02 | -1.38% | 1.45 | 1.47 | 1.37 |
| Mar 25, 2025 | 1.44 | -0.12 | -7.69% | 1.56 | 1.56 | 1.43 |
| Mar 24, 2025 | 1.55 | 0.00 | 0.00% | 1.55 | 1.61 | 1.51 |
| Mar 21, 2025 | 1.51 | 0.01 | 0.67% | 1.50 | 1.61 | 1.48 |
| Mar 20, 2025 | 1.54 | -0.02 | -1.28% | 1.56 | 1.57 | 1.49 |
| Mar 19, 2025 | 1.56 | -0.07 | -4.29% | 1.63 | 1.67 | 1.56 |
| Mar 18, 2025 | 1.64 | 0.04 | 2.50% | 1.60 | 1.67 | 1.55 |
| Mar 17, 2025 | 1.65 | 0.14 | 9.27% | 1.51 | 1.72 | 1.51 |
| Mar 14, 2025 | 1.49 | 0.00 | 0.00% | 1.49 | 1.55 | 1.49 |
| Mar 13, 2025 | 1.48 | -0.04 | -2.63% | 1.52 | 1.56 | 1.46 |
| Mar 12, 2025 | 1.53 | 0.00 | 0.00% | 1.53 | 1.57 | 1.47 |
| Mar 11, 2025 | 1.52 | -0.06 | -3.80% | 1.58 | 1.64 | 1.41 |
| Mar 10, 2025 | 1.38 | -0.16 | -10.39% | 1.54 | 1.63 | 1.34 |
| Mar 7, 2025 | 1.59 | 0.05 | 3.25% | 1.54 | 1.62 | 1.51 |
| Mar 6, 2025 | 1.54 | 0.08 | 5.48% | 1.46 | 1.59 | 1.46 |
| Mar 5, 2025 | 1.49 | 0.19 | 14.62% | 1.30 | 1.56 | 1.22 |
| Mar 4, 2025 | 1.30 | -0.09 | -6.47% | 1.39 | 1.47 | 1.23 |
| Mar 3, 2025 | 1.33 | -1.71 | -56.25% | 3.04 | 3.16 | 1.33 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Pliant Therapeutics, Inc. Company profile
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Pliant Therapeutics Inc revenues decreased 82% to $7.6M. Net loss increased from $41.5M to $97.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 14% to $73.6M (expense), General and administrative - Balancing increase of 39% to $21M (expense).
| Industry: | Pharmaceuticals (NEC) |
260 Littlefield Avenue
Suite 150
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com